Events

Association for Molecular Pathology 2025

Roche Diagnostics at AMP 2025

Join Roche in Booth No. 511 at the AMP 2025 Annual Meeting & Expo

Roche provides innovative clinical diagnostics, dPCR, next-gen sequencing, and digital solutions to empower your lab. We are dedicated to creating diagnostic tools and developing techniques that are tailored to individual genetic and disease profiles, meeting the demands of research and clinical practice to deliver on the promise of personalized healthcare.

Visit our booth to learn how our products and digital solutions can empower your healthcare institution with accurate results clinicians need to improve patient care in a rapidly changing and uncertain environment.

Visit our booth to explore the transformative power that lies within our partnerships and how our products can help researchers find the next revolutionary breakthrough and enable clinicians to improve patient care by providing accurate results.

Schedule

Convention Details

Nov. 13-15, 2025

Thomas M. Menino Convention and Exhibition Center
415 Summer St.
Boston, MA 02210

Booth No. 511

Request a product demo at AMP 2025

Request

AXELIOS 1 Sequencing Platform ^†

The AXELIOS 1 Sequencing Platform ^†, powered by Roche's innovative sequencing by expansion (SBX) technology^†, introduces a novel approach to sequencing through its unique biochemical approach of encoding target nucleic acid sequences into highly measurable Xpandomer molecules. This approach enables high-fidelity, single-molecule nanopore sequencing with a parallel CMOS-based sensor array.

With exceptional speed, throughput, and flexibility, the technology can sequence 500 million bases per second. SBX-Duplex (SBX-D) workflow, which links both strands of the target DNA in a single sequencing read, uses intramolecular consensus of the complementary reads to identify discordant calls and achieve high accuracy. Ideal for advanced oncology applications like whole genome sequencing (WGS), SBX technology excels in analyzing genomic DNA, even from challenging samples such as low-quality FFPE and cfDNA.

Learn more

AVENIO Tumor Tissue CGP Kit V2 ^*

Bring the power of Foundation Medicine® and Roche into your lab. The AVENIO Tumor Tissue CGP Kit V2 is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue-derived DNA samples. With a 335-gene panel aligned with the FoundationOne®CDx panel design and bioinformatics using the FoundationOne®Analysis Platform, the kit leverages the proven technology of Foundation Medicine and expertise of Roche to help your lab obtain reliable genomic insights.

Learn more

AVENIO Tumor Tissue CGP Automated Kit ^*

Designed to empower labs with accessible, efficient, and intuitive CGP capabilities; automated by the AVENIO Edge System^*, the AVENIO Tumor Tissue CGP Automated Kit has a total turnaround time of just 5 days, requiring only 3.5 hours of hands-on time from DNA extraction to result generation, and offers up to 24 hours of uninterrupted walkaway automation time.

Learn more

AVENIO Edge Liquid Handler ^* for NGS Library Prep

Simplify NGS library prep with the AVENIO Edge System, a fully automated platform for end-to-end library prep, target enrichment, quantification, pooling, and normalization. Designed for easy setup — even for users with no NGS or automation experience - with ready-to-load barcoded reagent cartridges and intuitive software.

Learn more

cobas® 5800 system

Introducing the next-generation of Molecular testing automation regardless of size, testing volume or mix. Improve productivity and reduce error, maximize the value of your lab space, scale efficiently as demands change, and ensure consistency across testing with standardized assays.

Learn more

LightCycler® PRO System

Light the way from research to clinical diagnostics with Roche's new IVD and RUO workflow capability real-time PCR system. Built upon proven technology, the LightCycler® PRO allows the ability to amplify confidence in your results, adapt quickly to your evolving testing needs, and simplify your workflow.

Learn more

Digital LightCycler® dPCR System

A digital PCR system for DNA and RNA with a 6-color capability for flexible, multiplexed biomarker detection. With advances in sensitivity, precision, flexibility, and integration, the Digital LightCycler® System is a powerful digital PCR system that aims to help laboratories push the boundaries of clinical research forward.

Learn more

navify® Mutation Profiler ^‡

Simplify NGS Tertiary Analysis

navify® Mutation Profiler ^‡ is a Next Generation Sequencing (NGS) reporting solution that can help labs & researchers confidently, clearly and efficiently interpret the significance of mutations. navify® Mutation Profiler increases lab efficiency and enables scalability by helping reduce curation time and by automating report generation.

Learn more

navify® Lab Operations

navify® Lab Operations automates the three main areas of the lab operations, pre-analytics, analytics and post analytics — but also extends beyond the lab to manage ordering, sample collection, validation and reporting. It enables a paperless workflow, and is structured around work areas that focus on the tasks in hand. The advanced workflow engine manages the sample processing and auto-validation enables efficient result management.

Learn more

Join Roche for the following Industry Events

Roche Corporate Workshops

Wednesday, November 12, 2025

Menino Convention and Exhibition Center | Location: 151AB, Level 1

LDT Automation: Leveraging the cobas® omni Utility Channel to Address Emerging Pathogens and the Constant Evolution of Testing Needs

8:00 a.m. - 8:50 a.m. EST

Speaker:
Ray Hein, Ph.D., Scientific Liaison Molecular, Medical and Scientific Affairs, Roche Diagnostics Corporation

This scientific workshop will explore strategies for automating laboratory-developed tests (LDTs) to detect emerging pathogens. It highlights the capabilities of the cobas® omni Utility Channel, an open-channel capability of the cobas® 5800/6800/8800 Systems. Participants will learn how to leverage the omni Utility Channel to transition manual workflows, from nucleic acid extraction to detection, into fully automated processes. The workshop will address the challenges associated with managing emerging health threats. Furthermore, the workshop will feature specific case studies demonstrating the omni Utility Channel's successful application in real-world scenarios (Candida auris, Measles, and Influenza H5N1), underscoring its flexibility and efficiency. Attendees will gain an understanding of how the omni Utility Channel can be utilized to adapt to evolving testing needs and respond to new pathogens.

Add to calendar: Outlook | Gmail | Apple

Purposeful Partnerships in Diagnostics: From Risk Reduction to Scalable Innovation

9:00 a.m. - 9:50 a.m. EST

Speakers:
Bernard Andruss, Ph.D., SVP & GM, Bio-Techne
Deepa Eveleigh, MS, MB(ASCP)CM, Director, Production-Custom & Lab Ops, Bio-Techne
John Milligan, Ph.D., Director, Product Development, Bio-Techne

Successful diagnostic assay development and manufacturing relies on strong partnerships rooted in quality, reliability, and a spirit of collaboration. Join R&D, Operations, and Quality leaders from Asuragen for a practical panel discussion on selecting the right contract manufacturing and raw material partners. Learn how to define key selection criteria, engage suppliers early, and collaborate to reduce business and technical risk. Gain insights into aligning supplier capabilities with sustainability goals and ensuring consistent product quality. This session provides actionable guidance for assay developers looking to build resilient, compliant, and innovation-ready partnerships across the diagnostic lifecycle.

Add to calendar: Outlook | Gmail | Apple

Navigating MET Aberrations in NSCLC: Implications for Pathologists, Oncologists, and for Targeted Therapies

10:00 a.m. - 10:50 a.m. EST

Speakers:
Dr. Michelle Shiller, Molecular Pathologist
Dr. Farah Khalil, Anatomical Pathologist
Dr. Xiuning Le, Medical Oncologist

Panel presentation and discussion between a Medical Oncologist, Pulmonologist and Molecular Pathologist to:

Understand patient populations affected by MET aberrations
Identify and discuss different types of MET aberrations in NSCLC
Explore therapy decisions related to MET aberrations
Discuss various testing methodologies for MET aberrations
Understand MET protein overexpression as a test and a target for therapy

Add to calendar: Outlook | Gmail | Apple

Sequencing by expansion (SBX), a Versatile, High-Throughput Single-Molecule Sequencing Technology for a Variety of Applications

11:00 a.m. - 11:50 a.m. EST

Speakers:

Mitu Chaudhary, Sr. Director, International Business Leader, Sequencing System, Roche Diagnostics Solutions
Mahdi Golkaram, Ph.D., Director of Bioinformatics, SBX algorithm development, Roche Diagnostics Solutions
Edwin Cuppen, Scientific Director, Hartwig Medical Foundation

This workshop will present how Roche’s sequencing by expansion (SBX) technology can enable Oncology research with its high accuracy and sensitivity. In the first presentation, Dr Edwin Cuppen will present on Hartwig Medical Foundation’s experiences with SBX, including in-depth data analyses of paired tumor-normal Whole-genome sequencing (WGS) and logistics of the workflow which is different from other technologies. WGS is rapidly advancing as an important technique in oncology research, offering a scalable solution for comprehensive genomic profiling and generating rich datasets for future applications in clinical development, translational research, and understanding tumorigenesis. In the second presentation, Dr Mahdi Golkaram will discuss SBX duplex methylation (SBX-DM) sequencing, which improves SNP error correction, enables high-throughput cfDNA WGS, and integrates methylation detection for enhanced MRD signal sensitivity.

Add to calendar: Outlook | Gmail | Apple

Optimizing Genomic Profiling in NSCLC: A Staged, Multimodal Approach

12:00 a.m. - 12:50 a.m. EST

Speakers:
Tara Love, Ph.D., Global Medical Affairs Lead, Precision Oncology & Informatics, Roche Diagnostics Solutions
Anthony Magliocco, MD, President and CEO of Protean Biodiagnostics

Add to calendar: Outlook | Gmail | Apple

New Frontiers in HRD Testing with a Novel Pan-Tumor HRD Signature

1:00 p.m. - 1:50 a.m. EST

Speakers:
Dr. Pranav Dorwal, MBBS, Molecular Anatomical Pathologist, Monash Health
Dr. Brennan Decker, Associate Director, Foundation Medicine

Add to calendar: Outlook | Gmail | Apple

* AVENIO Tumor Tissue CGP Portfolio and AVENIO Edge reagents and workflows are for Research Use Only. Not intended for diagnostic procedures.

† The AXELIOS 1 Sequencing Platform is in development and not commercially available in the U.S. When launched, the instrument will be Research Use Only (RUO). Not for use in diagnostic procedures.

The sequencing by expansion (SBX) technology is in development and not commercially available in the U.S.

‡ navify® Mutation Profiler is for Research Use Only. Not for use in diagnostic procedures.

FOUNDATIONONE is a trademark of Foundation Medicine, Inc.

User profile

Select your user profile